Anti-HIV Drug-Combination Nanoparticles Enhance Plasma Drug Exposure Duration as Well as Triple-Drug Combination Levels in Cells Within Lymph Nodes and Blood in Primates

Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection

Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,393 · see citing works

Molecular Biology of the Cell

Alberts, B., Johnson, A., Lewis, J. H., Morgan, D. O., RAFF, M. C., Roberts, K. J., & Walter, P. (2017) · W.W. Norton eBooks · doi:10.1201/9781315735368 · Cited by 7,937 · see citing works

Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Bøyum, A. (1968) · PubMed · Cited by 5,263 · see citing works

HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease

Pantaleo, G., Graziosi, C., Demarest, J. F., Butini, L., Montroni, M., Fox, C. H., Orenstein, J. M., Kotler, D. P., & Fauci, A. S. (1993) · Nature · doi:10.1038/362355a0 · Cited by 1,808 · see citing works

Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells

Siliciano, J. D., Kajdas, J., Finzi, D., Quinn, T. C., Chadwick, K., Margolick, J. B., Kovacs, C., Gange, S. J., & Siliciano, R. F. (2003) · Nature Medicine · doi:10.1038/nm880 · Cited by 1,703 · see citing works

Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues

Fletcher, C. V., Staskus, K. A., Wietgrefe, S. W., Rothenberger, M. K., Reilly, C., Chipman, J. G., Beilman, G. J., Khoruts, A., Thorkelson, A., Schmidt, T. E., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318249111 · Cited by 666 · see citing works

Kinetics of Response in Lymphoid Tissues to Antiretroviral Therapy of HIV-1 Infection

Cavert, W. P., Notermans, D. W., Staskus, K., Wietgrefe, S. W., Zupancic, M., Gebhard, K. H., Henry, K., Zhang, Z.-Q., Mills, R., McDade, H., et al. (1997) · Science · doi:10.1126/science.276.5314.960 · Cited by 622 · see citing works

Ritonavir

Hsu, A., Granneman, G. R., & Bertz, R. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835040-00002 · Cited by 486 · see citing works

Re-emergence of HIV after stopping therapy

Chun, T., Davey, R. T., Engel, D., Lane, H. C., & Fauci, A. S. (1999) · Nature · doi:10.1038/44755 · Cited by 424 · see citing works

Lymphatic uptake and biodistribution of liposomes after subcutaneous injection.

Oussoren, C., Zuidema, J., Crommelin, D. J. A., & Storm, G. (1997) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(97)00122-3 · Cited by 381 · see citing works

pH‐sensitive liposomes mediate cytoplasmic delivery of encapsulated macromolecules

Straubinger, R. M., Düzgüneş, N., & Papahadjopoulos, D. (1985) · FEBS Letters · doi:10.1016/0014-5793(85)80210-6 · Cited by 240 · see citing works

Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure

Wong, J. K., Günthard, H. F., Havlir, D. V., Zhang, Z.-Q., Haase, A. T., Ignacio, C. C., Kwok, S., Emini, E. A., & Richman, D. D. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12574 · Cited by 238 · see citing works

Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine

Notermans, D. W., Jurriaans, S., de Wolf, F., Foudraine, N. A., de Jong, J. J., Cavert, W. P., Schuwirth, C. M., Kauffmann, R. H., Meenhorst, P. L., McDade, H., et al. (1998) · AIDS · doi:10.1097/00002030-199802000-00006 · Cited by 185 · see citing works

Discrepancies between Protease Inhibitor Concentrations and Viral Load in Reservoirs and Sanctuary Sites in Human Immunodeficiency Virus-Infected Patients

Solas, C., Lafeuillade, A., Halfon, P., Chadapaud, S., Hittinger, G., & Lacarelle, B. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.1.238-243.2003 · Cited by 163 · see citing works

Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs

Gunaseelan, S., Gunaseelan, K., Deshmukh, M., Zhang, X., & Sinko, P. J. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.021 · Cited by 155 · see citing works

Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein

Storch, C. H., Theile, D., Lindenmaier, H., Haefeli, W. E., & Weiß, J. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.01.027 · Cited by 154 · see citing works

Lymph nodes harbor viral reservoirs that cause rebound of plasma viremia in SIV-infected macaques upon cessation of combined antiretroviral therapy

Horiike, M., Iwami, S., Kodama, M., Sato, A., Watanabe, Y., Yasui, M., Ishida, Y., Kobayashi, T., Miura, T., & Igarashi, T. (2011) · Virology · doi:10.1016/j.virol.2011.11.024 · Cited by 116 · see citing works

Nanoformulated Antiretroviral Drug Combinations Extend Drug Release and Antiretroviral Responses in HIV-1-Infected Macrophages: Implications for NeuroAIDS Therapeutics

Nowacek, A. S., McMillan, J., Miller, R., Anderson, A. K., Rabinow, B. E., & Gendelman, H. E. (2010) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-010-9198-7 · Cited by 107 · see citing works

Pharmacokinetic Properties of Nucleoside/Nucleotide Reverse Transcriptase Inhibitors

Piliero, P. J. (2004) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000137001.40505.56 · Cited by 94 · see citing works

Lipid–Drug Association Enhanced HIV-1 Protease Inhibitor Indinavir Localization in Lymphoid Tissues and Viral Load Reduction: A Proof of Concept Study in HIV-2287-Infected Macaques

Kinman, L., Brodie, S. J., Tsai, C., Bui, T., Larsen, K., Schmidt, A. M., Anderson, D., Morton, W. R., Hu, S.-L., & Ho, R. J. Y. (2003) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200312010-00005 · Cited by 86 · see citing works

Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral‐naïve patients

Cicconi, P., Cozzi‐Lepri, A., Castagna, A., Trecarichi, E. M., Antinori, A., Gatti, F., Cassola, G., Sighinolfi, L., Castelli, P., & Monforte, A. D. (2009) · HIV Medicine · doi:10.1111/j.1468-1293.2009.00750.x · Cited by 84 · see citing works

Polymeric Nanoparticles Containing Combination Antiretroviral Drugs for HIV Type 1 Treatment

Shibata, A., Mcmullen, E., Pham, A. D., Belshan, M., Sanford, B. L., Zhou, Y., Goede, M., Date, A. A., & Destache, C. J. (2013) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2012.0301 · Cited by 79 · see citing works

Residual Human Immunodeficiency Virus Type 1 RNA in Lymphoid Tissue of Patients with Sustained Plasma RNA of <200 Copies/mL

Lafeuillade, A., Chollet, L., Hittinger, G., Profizi, N., Costes, O., & Poggi, C. (1998) · The Journal of Infectious Diseases · doi:10.1086/517362 · Cited by 65 · see citing works

Novel Gd Nanoparticles Enhance Vascular Contrast for High-Resolution Magnetic Resonance Imaging

Bui, T., Stevenson, J., Hoekman, J., Zhang, S., Maravilla, K. R., & Ho, R. J. Y. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013082 · Cited by 57 · see citing works

Solid lipid nanoparticles comprising internal Compritol 888 ATO, tripalmitin and cacao butter for encapsulating and releasing stavudine, delavirdine and saquinavir

Kuo, Y., & Chung, C. (2011) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2011.07.060 · Cited by 55 · see citing works

Short-Term Discontinuation of HAART Regimens More Common in Vulnerable Patient Populations

Robison, L. S., Westfall, A. O., Mugavero, M. J., Kempf, M.-C., Cole, S. R., Allison, J. J., Willig, J. H., Raper, J. L., Wilcox, C. M., & Saag, M. S. (2008) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2008.0083 · Cited by 54 · see citing works

Enhanced Anti-HIV Efficacy of Indinavir After Inclusion in CD4-Targeted Lipid Nanoparticles

Endsley, A. N., & Ho, R. J. Y. (2012) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182653c1f · Cited by 46 · see citing works

Response to

Khanlou, H., Louie, S. G., & Farthing, C. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000214822.33905.87 · Cited by 45 · see citing works

pH-Dependent Interactions of Indinavir and Lipids in Nanoparticles and Their Ability to Entrap a Solute

Choi, S., Bui, T., & Ho, R. J. Y. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21020 · Cited by 36 · see citing works

Novel Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneous Detection of Anti-HIV Drugs Lopinavir, Ritonavir, and Tenofovir in Plasma

Koehn, J., & Ho, R. J. Y. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02748-13 · Cited by 34 · see citing works

Lymphoid tissue viral burden and duration of viral suppression in plasma

Martínez, E., Arnedo, M., Giner, V., Gil, C., Caballero, M., Alós, L., García, F., Holtzer, C. D., Mallolas, J., Miró, J. M., et al. (2001) · AIDS · doi:10.1097/00002030-200108170-00004 · Cited by 19 · see citing works

Nanotechnology approaches for global infectious diseases

Kirtane, A. R., Verma, M., Karandikar, P., Furin, J., Langer, R., & Traverso, G. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00866-8 · Cited by 520 · see citing works

Nanomaterials Designed for Antiviral Drug Delivery Transport across Biological Barriers

Cojocaru, F.-D., Botezat, D., Gardikiotis, I., Urîtu, C. M., Dodi, G., Trandafir, L. M., Rezuș, C., Rezuş, E., Tamba, B.-I., & Mihai, C. T. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020171 · Cited by 207 · see citing works

Nanomaterials and Nanotechnology-Associated Innovations against Viral Infections with a Focus on Coronaviruses

Nasrollahzadeh, M., Sajjadi, M., Soufi, G. J., Iravani, S., & Varma, R. S. (2020) · Nanomaterials · doi:10.3390/nano10061072 · Cited by 159 · see citing works

Nanostructures for the Inhibition of Viral Infections

Szunerits, S., Barras, A., Khanal, M., Pagneux, Q., & Boukherroub, R. (2015) · Molecules · doi:10.3390/molecules200814051 · Cited by 132 · see citing works

Creation of a long-acting nanoformulated dolutegravir

Sillman, B., Bade, A. N., Dash, P. K., Bhargavan, B., Kocher, T., Mathews, S., Su, H., Kanmogne, G. D., Poluektova, L. Y., Gorantla, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02885-x · Cited by 125 · see citing works

Nanoparticles in Antiviral Therapy

Milovanović, M., Arsenijević, A., Milovanović, J., Kanjevac, T., & Arsenijević, N. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-52733-0.00014-8 · Cited by 114 · see citing works

Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response

Yu, J., Mu, Q., Fung, M., Xu, X., Zhu, L., & Ho, R. J. Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108108 · Cited by 103 · see citing works

Nanoparticles-in-film for the combined vaginal delivery of anti-HIV microbicide drugs

Cunha-Reis, C., Machado, A., Barreiros, L., Araújo, F., Nunes, R., Seabra, V., Ferreira, D., Segundo, M. A., Sarmento, B., & das Neves, J. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.09.020 · Cited by 95 · see citing works

Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles

Zhou, T., Su, H., Dash, P. K., Lin, Z., Shetty, B. L. D., Kocher, T., Szlachetka, A. M., Lamberty, B. G., Fox, H. S., Poluektova, L. Y., et al. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.10.023 · Cited by 89 · see citing works

Combination drug therapy via nanocarriers against infectious diseases

Walvekar, P., Gannimani, R., & Govender, T. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.10.017 · Cited by 83 · see citing works

Development and in vivo safety assessment of tenofovir-loaded nanoparticles-in-film as a novel vaginal microbicide delivery system

Machado, A., Cunha-Reis, C., Araújo, F., Nunes, R., Seabra, V., Ferreira, D., das Neves, J., & Sarmento, B. F. C. C. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.08.018 · Cited by 70 · see citing works

Recent advances in long-acting nanoformulations for delivery of antiretroviral drugs

Surve, D. H., & Jindal, A. B. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.022 · Cited by 68 · see citing works

Long-acting slow effective release antiretroviral therapy

Edagwa, B., McMillan, J., Sillman, B., & Gendelman, H. E. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2017.1288212 · Cited by 69 · see citing works

Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies

Giardiello, M., Liptrott, N. J., McDonald, T. O., Moss, D., Siccardi, M., Martin, P., Smith, D., Gurjar, R., Rannard, S. P., & Owen, A. (2016) · Nature Communications · doi:10.1038/ncomms13184 · Cited by 63 · see citing works

Subcutaneous drug delivery from nanoscale systems

Tomasini, L., Ferrere, M., & Nicolas, J. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00161-w · Cited by 59 · see citing works

Analysis of multi-drug cancer nanomedicine

Benderski, K., Lammers, T., & Sofias, A. M. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-01932-1 · Cited by 54 · see citing works

Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection

Nayan, M. U., Sillman, B., Hasan, M., Deodhar, S., Das, S., Sultana, A., Le, N. T. H., Soriano, V., Edagwa, B., & Gendelman, H. E. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115009 · Cited by 57 · see citing works

Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma

Kraft, J. C., McConnachie, L. A., Koehn, J., Kinman, L., Collins, C. J., Shen, D. D., Collier, A. C., & Ho, R. J. Y. (2017) · AIDS · doi:10.1097/qad.0000000000001405 · Cited by 53 · see citing works

Triple Drug Combination of Zidovudine, Efavirenz and Lamivudine Loaded Lactoferrin Nanoparticles: an Effective Nano First-Line Regimen for HIV Therapy

Kumar, P., Lakshmi, Y. S., & Kondapi, A. K. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-2048-4 · Cited by 52 · see citing works

Nanotechnology approaches to eradicating HIV reservoirs

Cao, S., & Woodrow, K. A. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.06.002 · Cited by 49 · see citing works

Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation

Kraft, J. C., McConnachie, L. A., Koehn, J., Kinman, L., Sun, J., Collier, A. C., Collins, C. J., Shen, D. D., & Ho, R. J. Y. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.003 · Cited by 49 · see citing works

HIV and the Macrophage: From Cell Reservoirs to Drug Delivery to Viral Eradication

Herskovitz, J., & Gendelman, H. E. (2018) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-018-9785-6 · Cited by 46 · see citing works

The Lymph Node Reservoir: Physiology, HIV Infection, and Antiretroviral Therapy

Scholz, E. M. B., & Kashuba, A. D. M. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2186 · Cited by 46 · see citing works

Tailoring biomaterials for vaccine delivery

Zhuo, Y., Zeng, H., Su, C., Lv, Q., Cheng, T., & Lei, L. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02758-0 · Cited by 47 · see citing works

A potential long-acting bictegravir loaded nano-drug delivery system for HIV-1 infection: A proof-of-concept study

Mandal, S., Prathipati, P. K., Belshan, M., & Destache, C. J. (2019) · Antiviral Research · doi:10.1016/j.antiviral.2019.04.007 · Cited by 44 · see citing works

An Enhanced Emtricitabine-Loaded Long-Acting Nanoformulation for Prevention or Treatment of HIV Infection

Mandal, S., Belshan, M., Holec, A. D., Zhou, Y., & Destache, C. J. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01475-16 · Cited by 42 · see citing works

Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model

Destache, C. J., Mandal, S., Yuan, Z., Kang, G., Date, A. A., Lu, W., Shibata, A., Pham, R. N., Bruck, P. T., Rezich, M., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00450-16 · Cited by 40 · see citing works

Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection

McConnachie, L. A., Kinman, L., Koehn, J., Kraft, J. C., Lane, S., Lee, W., Collier, A. C., & Ho, R. J. Y. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.03.005 · Cited by 40 · see citing works

Hybrid nanocarriers incorporating mechanistically distinct drugs for lymphatic CD4 + T cell activation and HIV-1 latency reversal

Cao, S., Slack, S. D., Levy, C., Hughes, S. M., Jiang, Y., Yogodzinski, C., Roychoudhury, P., Jerome, K. R., Schiffer, J. T., Hladik, F., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav6322 · Cited by 39 · see citing works

Nanotechnology advances in pathogen- and host-targeted antiviral delivery: multipronged therapeutic intervention for pandemic control

Yang, K.-C., Lin, J.-C., Tsai, H.-H., Hsu, C.-Y., Shih, V., & Hu, C.-M. J. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-00965-y · Cited by 39 · see citing works

Targeted delivery of lopinavir to HIV reservoirs in the mesenteric lymphatic system by lipophilic ester prodrug approach

Qin, C., Chu, Y., Feng, W., Fromont, C., He, S., Ali, J., Lee, J. B., Zgair, A., Berton, M., Bettonte, S., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.10.036 · Cited by 39 · see citing works

Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook

Mu, Q., Yu, J., McConnachie, L. A., Kraft, J. C., Gao, Y., Gulati, G. K., & Ho, R. J. Y. (2017) · Journal of drug targeting · doi:10.1080/1061186x.2017.1419363 · Cited by 39 · see citing works

Nanodrug Formulations to Enhance HIV Drug Exposure in Lymphoid Tissues and Cells: Clinical Significance and Potential Impact on Treatment and Eradication of HIV/AIDS

Shao, J., Kraft, J. C., Li, B., Yu, J., Freeling, J. P., Koehn, J., & Ho, R. J. Y. (2016) · Nanomedicine · doi:10.2217/nnm.16.1 · Cited by 34 · see citing works

Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery

Hu, M., Patel, S. K., Zhou, T., & Rohan, L. C. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.018 · Cited by 35 · see citing works

Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques

McMillan, J., Szlachetka, A., Slack, L., Sillman, B., Lamberty, B., Morsey, B., Callen, S., Gautam, N., Alnouti, Y., Edagwa, B., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01316-17 · Cited by 32 · see citing works

Architectured Therapeutic and Diagnostic Nanoplatforms for Combating SARS-CoV-2: Role of Inorganic, Organic, and Radioactive Materials

Pandey, A. P., Nikam, A. N., Mutalik, S. P., Fernandes, G. J., Shreya, A. B., Padya, B. S., Raychaudhuri, R., Kulkarni, S., Prassl, R., Subramanian, S., et al. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c01243 · Cited by 31 · see citing works

Chronic Hepatitis B Infection: New Approaches towards Cure

Ogunnaike, M., Das, S., Raut, S. S., Sultana, A., Nayan, M. U., Ganesan, M., Edagwa, B., Osna, N. A., & Poluektova, L. Y. (2023) · Biomolecules · doi:10.3390/biom13081208 · Cited by 33 · see citing works

Past, Present, and Future Drug Delivery Systems for Antiretrovirals

Kirtane, A. R., Langer, R., & Traverso, G. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.09.015 · Cited by 28 · see citing works

Reverse Transcriptase Inhibitors Nanosystems Designed for Drug Stability and Controlled Delivery

Grande, F., Ioele, G., Occhiuzzi, M. A., Luca, M. D., Mazzotta, E., Ragno, G., Garofalo, A., & Muzzalupo, R. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11050197 · Cited by 27 · see citing works

Tumor-induced lymph node alterations detected by MRI lymphography using gadolinium nanoparticles

Partridge, S. C., Kurland, B. F., Liu, C.-L., Ho, R. J. Y., & Ruddell, A. (2015) · Scientific Reports · doi:10.1038/srep15641 · Cited by 23 · see citing works

Long-Acting Efavirenz and HIV-1 Fusion Inhibitor Peptide Co-loaded Polymer–Lipid Hybrid Nanoparticles: Statistical Optimization, Cellular Uptake, and In Vivo Biodistribution

Surve, D. H., Jirwankar, Y. B., Dighe, V. D., & Jindal, A. B. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00773 · Cited by 22 · see citing works

Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 2: Model for the Drug-combination Nanoparticles

Perazzolo, S., Shen, D. D., & Ho, R. J. Y. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.10.009 · Cited by 21 · see citing works

Extended cell and plasma drug levels after one dose of a three-in-one nanosuspension containing lopinavir, efavirenz, and tenofovir in nonhuman primates

Koehn, J., Iwamoto, J. F., Kraft, J. C., McConnachie, L. A., Collier, A. C., & Ho, R. J. Y. (2018) · AIDS · doi:10.1097/qad.0000000000001969 · Cited by 21 · see citing works

Controlled Solvent Removal from Antiviral Drugs and Excipients in Solution Enables the Formation of Novel Combination Multi-Drug-Motifs in Pharmaceutical Powders Composed of Lopinavir, Ritonavir and Tenofovir

Yu, J., Yu, D.-N., Lane, S., McConnachie, L. A., & Ho, R. J. Y. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.08.003 · Cited by 19 · see citing works

Integration of Computational and Experimental Approaches to Elucidate Mechanisms of First-Pass Lymphatic Drug Sequestration and Long-Acting Pharmacokinetics of the Injectable Triple-HIV Drug Combination TLC-ART 101

Perazzolo, S., Shireman, L. M., McConnachie, L. A., Koehn, J., Kinman, L., Lee, W., Lane, S., Collier, A. C., Shen, D. D., & Ho, R. J. Y. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.01.016 · Cited by 20 · see citing works

Gene Transfer in Adeno-Associated Virus Seropositive Rhesus Macaques Following Rapamycin Treatment and Subcutaneous Delivery of AAV6, but Not Retargeted AAV6 Vectors

Stone, D., Kenkel, E. J., Loprieno, M. A., Tanaka, M., Feelixge, H. S. D. S., Kumar, A. J., Stensland, L., Obenza, W., Wangari, S., Ahrens, C. Y., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.113 · Cited by 20 · see citing works

Battle of the milky way: Lymphatic targeted drug delivery for pathogen eradication

Taheri, A., Bremmell, K. E., Joyce, P., & Prestidge, C. A. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.10.002 · Cited by 19 · see citing works

Long-Acting Treatments for Hepatitis B

Thomas, D. L., Kiser, J. J., & Baum, M. M. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac718 · Cited by 18 · see citing works

The Potential of Long-Acting, Tissue-Targeted Synthetic Nanotherapy for Delivery of Antiviral Therapy Against HIV Infection

Andersen, A. H. F., & Tolstrup, M. (2020) · Viruses · doi:10.3390/v12040412 · Cited by 18 · see citing works

Systems Approach to targeted and long-acting HIV/AIDS therapy

Ho, R. J. Y., Yu, J., Li, B., Kraft, J. C., Freeling, J. P., Koehn, J., & Shao, J. (2015) · Drug Delivery and Translational Research · doi:10.1007/s13346-015-0254-y · Cited by 17 · see citing works

A Concept Evaluation Study of a New Combination Bictegravir plus Tenofovir Alafenamide Nanoformulation with Prolonged Sustained-Drug-Release Potency for HIV-1 Preexposure Prophylaxis

Mandal, S., Prathipati, P. K., Sunagawa, S. W., & Destache, C. J. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02320-20 · Cited by 16 · see citing works

Recent advances in nanoformulation development of Ritonavir, a key protease inhibitor used in the treatment of HIV-AIDS

Jitta, S. R., Salwa, Bhaskaran, N. A., Marques, S. M., & Kumar, L. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2121817 · Cited by 16 · see citing works

Pharmacology of HIV Cure: Site of Action

Devanathan, A. S., & Cottrell, M. L. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2187 · Cited by 15 · see citing works

Early Stage HIV Management and Reduction of Stavudine-Induced Hepatotoxicity in Rats by Experimentally Developed Biodegradable Nanoparticles

Ghosh, S., Mondal, L., Chakraborty, S., & Mukherjee, B. (2016) · AAPS PharmSciTech · doi:10.1208/s12249-016-0539-6 · Cited by 14 · see citing works

Emerging Trends in the Long-Acting Antiretroviral Therapy: Current Status and Therapeutic Challenges

Labh, R., & Gupta, R. (2020) · Current HIV Research · doi:10.2174/1570162x18666200824104140 · Cited by 13 · see citing works

A novel formulation enabled transformation of 3-HIV drugs tenofovir–lamivudine–dolutegravir from short-acting to long-acting all-in-one injectable

Perazzolo, S., Stephen, Z. R., Eguchi, M., Xu, X., Fratte, R. D., Collier, A. C., Melvin, A. J., & Ho, R. J. Y. (2023) · AIDS · doi:10.1097/qad.0000000000003706 · Cited by 12 · see citing works

Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 1: Model for the Free-Drug Mixture

Perazzolo, S., Shireman, L. M., Shen, D. D., & Ho, R. J. Y. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.10.007 · Cited by 11 · see citing works

Physiologically based Pharmacokinetic Model Validated to Enable Predictions Of Multiple Drugs in a Long-acting Drug-combination Nano-Particles (DcNP): Confirmation with 3 HIV Drugs, Lopinavir, Ritonavir, and Tenofovir in DcNP Products

Perazzolo, S., Shen, D. D., Scott, A. M., & Ho, R. J. Y. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.02.018 · Cited by 11 · see citing works

Recent Advances in Antiviral Drug Delivery Strategies

Rana, D., Prajapati, A., Karunakaran, B., Vora, L. K., Benival, D. M., Jindal, A. B., Patel, R., Joshi, V. M., Jamloki, A., & Shah, U. A. (2025) · AAPS PharmSciTech · doi:10.1208/s12249-025-03053-3 · Cited by 10 · see citing works

Prodrug Therapies for Infectious and Neurodegenerative Diseases

Marković, M., Deodhar, S., Machhi, J., Yeapuri, P., Saleh, M., Edagwa, B., Mosley, R. L., & Gendelman, H. E. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030518 · Cited by 10 · see citing works

Development of NanoART for HIV Treatment: Minding the Cytochrome P450 (CYP) Enzymes.

Midde, N. M., & Kumar, S. (2015) · PubMed · Cited by 9 · see citing works

Stimuli-sensitive nanoparticles for multiple anti-HIV microbicides

Giri, N., Oh, B., & Lee, C. (2016) · Journal of Nanoparticle Research · doi:10.1007/s11051-016-3449-3 · Cited by 9 · see citing works

Drug delivery and innovative pharmaceutical development in mimicking the red blood cell membrane

Naeem, S., Kiew, L. V., Yong, C. L., Yin, Y. T., & Misran, M. (2015) · Reviews in Chemical Engineering · doi:10.1515/revce-2015-0010 · Cited by 8 · see citing works

In vitro & in vivo evaluations of PLGA nanoparticle based combinatorial drug therapy for baclofen and lamotrigine for neuropathic pain management

Nigam, K., Kaur, A., Tyagi, A. K., Manda, K., Goswami, N., Nematullah, M., Khan, F., Gabrani, R., Gauba, P., & Dang, S. (2022) · Journal of Microencapsulation · doi:10.1080/02652048.2022.2041751 · Cited by 8 · see citing works

Novel Long-Acting Drug Combination Nanoparticles Composed of Gemcitabine and Paclitaxel Enhance Localization of Both Drugs in Metastatic Breast Cancer Nodules

Yu, J., Mu, Q., Perazzolo, S., Griffin, J. I., Zhu, L., McConnachie, L. A., Shen, D. D., & Ho, R. J. Y. (2020) · Pharmaceutical Research · doi:10.1007/s11095-020-02888-8 · Cited by 8 · see citing works

Biocompatible metal–organic frameworks as promising platforms to eradicate HIV reservoirs ex vivo in people living with HIV

Lebrón, J. A., Ostos, F. J., Martínez-Santa, M., Moscoso, F. G., López‐López, M., Moyá, M. L., Bernal, E., Bachiller, S., Gónzalez‐Ulloa, G., Rodríguez‐Lucena, D., et al. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb00272e · Cited by 6 · see citing works

Applications of Nanomaterials in Medicine: Current Status and Future Scope

Kakodkar, S., Dhawal, P. P., & Kadam, J. (2023) · Springer eBooks · doi:10.1007/978-981-99-5281-6_4 · Cited by 7 · see citing works

Bending properties of two- and three-dimensional-shaped nanoparticles fabricated via substrate conformal imprint lithography

Reuter, S., Smolarczyk, M., Istock, A., Ha, U., Schneider, O., Worapattrakul, N., Nazemroaya, S., Hoang, H., Gomer, L., Pilger, F., et al. (2017) · Journal of Nanoparticle Research · doi:10.1007/s11051-017-3886-7 · Cited by 6 · see citing works

The quest for a better fight: How can nanomaterials address the current therapeutic and diagnostic obstacles in the fight against COVID-19?

Ranjbar, S., Fatahi, Y., & Atyabi, F. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102899 · Cited by 6 · see citing works

Understanding the Pharmacology and Pharmacotherapeutics for Infectious Diseases

Agrawal, N., Singh, I. P., Khanna, M., Dhawan, G., Kumar, P., & Dhawan, U. (2022) · Springer eBooks · doi:10.1007/978-981-16-9190-4_3 · Cited by 3 · see citing works

Nanoparticle-Based Drug Delivery for Infectious Diseases

Sultana, A., & Nayan, M. U. (2024) · Springer eBooks · doi:10.1007/978-981-97-3925-7_13 · Cited by 2 · see citing works

Polymeric and lipidic nanoparticles in transforming anti-HIV combinational therapy: can they turn the tide?

Popli, P., Meduri, R. T., Sharma, T., Challa, R. R., Vallamkonda, B., Satti, P., Singh, T. G., & Swami, R. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04169-w · Cited by 2 · see citing works

Nanoparticle Encapsulation for Antiretroviral Pre-Exposure Prophylaxis

Shibata, A., Khandalavala, K., Mandal, S., Pham, R. N., & Destache, C. J. (2017) · Journal of Nanotechnology and Materials Science · doi:10.15436/2377-1372.17.1583 · Cited by 2 · see citing works

Peptide- and Protein-Based Nanoparticles

Negah, S. S., Khawaja, A. M., Kendall, L., & Heiss, J. D. (2024) · Springer eBooks · doi:10.1007/978-3-030-80662-0_5 · Cited by 1 · see citing works

Harnessing albumin as a carrier for the delivery of anti-HIV drugs to the lymphatic system

Zhang, Z., Huang, Y., West, R. E., Mahesh, D., Oberly, P. J., Li, S., Luo, Z., Chen, Y., Huang, H., Bain, D. J., et al. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.11.017 · Cited by 1 · see citing works

Antiretroviral Drug Penetration into Lymphoid Tissue

Fletcher, C. V., & Podany, A. T. (2015) · Springer eBooks · doi:10.1007/978-1-4614-9610-6_436-1 · Cited by 1 · see citing works

Antiretroviral Drug Penetration into Lymphoid Tissue

Fletcher, C. V., & Podany, A. T. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7101-5_436 · Cited by 1 · see citing works

Multidrug nanosuspensions

Tartaglia, A. (2018) · AIDS · doi:10.1097/qad.0000000000001971

Nanocombinational therapies for infectious disorders

Sahoo, A., Dwivedi, K., Alam, K., & Rahman, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13337-4.00018-5

Nanoformulation and Preclinical Evaluation of Dihydroartemisinin–Lumefantrine and Primaquine as Combined Antimalarial Therapy

Odera, P. A., Otieno, G., Onyango, J. O., Ogutu, B. R., Owuor, J. J., Oloo, F. A., Ongas, M. O., Swai, H., & Gathirwa, J. W. (2025) · Journal of Nanotechnology · doi:10.1155/jnt/5162847 · Cited by 1 · see citing works

Biocompatible Nanocomposites for Vaccine Delivery

Rajakumari, R., Sangeetha, G., Kalarikkal, N., & Thomas, S. (2025) · Advanced structured materials · doi:10.1007/978-981-96-7450-3_9

Synthèse et évaluation de prodrogues polymères hydrophiles pour l'injection sous-cutanée de principes actifs cytotoxiques

Ferrere, M. (2021) · doi:10.70675/d65ba197zeb55z43b0z91cez0eee28386c35

Synthesis, evaluation and administration of water-soluble polymer prodrugs for the subcutaneous administration of vesicant anticancer drugs

Tomasini, L. (2023) · doi:10.70675/20a14da4z235cz4110z85afza39557c573bb

A novel all-in-one injectable composed of tenofovir alafenamide–dolutegravir–lamivudine exhibits long-acting plasma and cell drug persistence for 8 weeks

Stephen, Z. R., Perazzolo, S., Duan, L., Eguchi, M., Tian, B., Klein, K., Kinman, L., Fratte, R. D., Waldorf, K. M. A., Barton, T., et al. (2026) · AIDS · doi:10.1097/qad.0000000000004531

Understanding the influence of stabiliser selection and concentration on the physical stability of dual-drug co-suspensions

Sørensen, M. D. M., Skjelborg, J. B., Henningsen, L. M., & Holm, R. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127467

Long-acting three-drug combination anti-HIV nanoparticles enhance drug exposure in primate plasma and cells within lymph nodes and blood

Freeling, J. P., Koehn, J., Shu, C., Sun, J., & Ho, R. J. Y. (2014) · AIDS · doi:10.1097/qad.0000000000000421 · Cited by 69 · see citing works

Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma

Kraft, J. C., McConnachie, L. A., Koehn, J., Kinman, L., Collins, C. J., Shen, D. D., Collier, A. C., & Ho, R. J. Y. (2017) · AIDS · doi:10.1097/qad.0000000000001405 · Cited by 53 · see citing works

Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection

McConnachie, L. A., Kinman, L., Koehn, J., Kraft, J. C., Lane, S., Lee, W., Collier, A. C., & Ho, R. J. Y. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.03.005 · Cited by 40 · see citing works

Antiretroviral nanoparticles

Freeling, J. P., & Ho, R. J. Y. (2015) · AIDS · doi:10.1097/qad.0000000000000600

Extended cell and plasma drug levels after one dose of a three-in-one nanosuspension containing lopinavir, efavirenz, and tenofovir in nonhuman primates

Koehn, J., Iwamoto, J. F., Kraft, J. C., McConnachie, L. A., Collier, A. C., & Ho, R. J. Y. (2018) · AIDS · doi:10.1097/qad.0000000000001969 · Cited by 21 · see citing works